South Korean researchers have developed a method to create mini-brains from patient blood cells to monitor Alzheimer's disease in real time [1, 2].
This development is significant because Alzheimer's pathology typically begins years before clinical symptoms appear. A non-invasive, blood-based organoid model could allow doctors to detect the disease earlier and provide a more efficient platform for testing new therapeutic drugs [1, 2].
The research was conducted at KAIST and Korea University. The team, which included KAIST post-doctoral researcher Han Jeong-mu and Korea University professor Park Hee-ho, utilized fluorescence-lifetime imaging to observe cellular changes and the accumulation of proteins associated with the disease [1, 2].
By using this specific imaging technology, the researchers can capture data at speeds similar to fluorescence microscopy. This allows the team to monitor living samples as they evolve without destroying the tissue [1].
"We have become able to observe the pathological changes of Alzheimer's in real time using brain organoids derived from blood," Park said [2].
"The ability to obtain images at high speeds provides the distinct advantage of monitoring actual living samples in real time," Han said [1].
The process involves transforming a patient's blood cells into a brain organoid, a three-dimensional tissue structure that mimics the human brain's architecture. Once the organoid is grown, researchers can apply the imaging technology to track how Alzheimer's progresses within that specific patient's genetic context [1, 2].
“A blood-based, non-invasive organoid model could enable earlier diagnosis and accelerate therapeutic development.”
The shift toward blood-derived organoids represents a move toward personalized medicine for neurodegenerative diseases. By creating a patient-specific 'mini-brain' outside the body, clinicians can potentially predict disease progression and test drug efficacy without risking patient safety or relying on invasive brain biopsies.
